{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T21:53:27Z","timestamp":1773611607705,"version":"3.50.1"},"reference-count":88,"publisher":"Wiley","issue":"3","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd015125","type":"journal-article","created":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T11:01:22Z","timestamp":1646823682000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Inhaled corticosteroids for the treatment of COVID-19"],"prefix":"10.1002","volume":"2022","author":[{"given":"Mirko","family":"Griesel","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Intensive Care; University of Leipzig Medical Center; Leipzig Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carina","family":"Wagner","sequence":"additional","affiliation":[{"name":"Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agata","family":"Mikolajewska","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Respiratory Medicine; Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin; Berlin Germany"},{"name":"Centre for Biological Threats and Special Pathogens (ZBS), Strategy and Incident Response, Clinical Management and Infection Control; Robert Koch Institute; Berlin Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miriam","family":"Stegemann","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Respiratory Medicine; Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin; Berlin Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Falk","family":"Fichtner","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Intensive Care; University of Leipzig Medical Center; Leipzig Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria-Inti","family":"Metzendorf","sequence":"additional","affiliation":[{"name":"Cochrane Metabolic and Endocrine Disorders Group; Institute of General Practice, Medical Faculty of the Heinrich-Heine-University D\u00fcsseldorf; D\u00fcsseldorf Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Avinash Anil","family":"Nair","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine; Christian Medical College; Vellore India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jefferson","family":"Daniel","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine; Christian Medical College; Vellore India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna-Lena","family":"Fischer","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Intensive Care; University of Leipzig Medical Center; Leipzig Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Skoetz","sequence":"additional","affiliation":[{"name":"Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,3,9]]},"reference":[{"key":"10.1002\/14651858.CD015125-BIB0001|cit1","first-page":"1","article-title":"A randomised controlled trial of inhaled ciclesonide for outpatient treatment of symptomatic COVID-19 infections","author":"Clemency","year":"2021","journal-title":"medRxiv"},{"issue":"7","key":"10.1002\/14651858.CD015125-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S2213-2600(21)00160-0","article-title":"Inhaled budesonide in the treatment of early COVID-19(STOIC): a phase 2, open-label, randomised controlled trial","volume":"9","author":"Ramakrishnan","year":"2021","journal-title":"Lancet Respiratory Medicine"},{"key":"10.1002\/14651858.CD015125-BIB0003|cit3","first-page":"1","article-title":"Inhaled budesonide in the treatment of early COVID-19 illness: a randomised controlled trial","author":"Ramakrishnan","year":"2021","journal-title":"medRxiv"},{"key":"10.1002\/14651858.CD015125-BIB0004|cit4","unstructured":"STOIC Patient information sheet stoic.ndm.ox.ac.uk\/patient-information-sheet"},{"key":"10.1002\/14651858.CD015125-BIB0005|cit5","first-page":"1","article-title":"Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial","author":"Yu","year":"2021","journal-title":"medRxiv"},{"issue":"10301","key":"10.1002\/14651858.CD015125-BIB0006|cit6","first-page":"1","article-title":"Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial","volume":"398","author":"Yu","year":"2021","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD015125-BIB0007|cit7","unstructured":"Effect of inhaled corticosteroids in the treatment of anosmia in patients with COVID-19 en.irct.ir\/trial\/48379"},{"key":"10.1002\/14651858.CD015125-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2021\/2129006","article-title":"Efficacy of colchicine and budesonide in improvement outcomes of patients with coronavirus infection 2019 in Damascus, Syria: a randomised control trial","volume":"2021","author":"Alsultan","year":"2021","journal-title":"Interdisciplinary Perspectives on Infectious Diseases"},{"key":"10.1002\/14651858.CD015125-BIB0009|cit9","unstructured":"Treatment with inhaled corticoids in patients with COVID-19 admitted to hospital with pneumonia www.clinicaltrialsregister.eu\/ctr-search\/search?query=2020-001616-18"},{"key":"10.1002\/14651858.CD015125-BIB0010|cit10","unstructured":"Inhaled corticosteroid treatment of COVID-19 patients with pneumonia www.clinicaltrials.gov\/ct2\/show\/NCT04355637"},{"key":"10.1002\/14651858.CD015125-BIB0011|cit11","unstructured":"Protective role of inhaled steroids for Covid-19 infection (INHASCO) clinicaltrials.gov\/ct2\/show\/NCT04331054"},{"key":"10.1002\/14651858.CD015125-BIB0012|cit12","unstructured":"Inhaled ciclesonide for outpatients with COVID19 (CONTAIN) clinicaltrials.gov\/ct2\/show\/NCT04435795"},{"issue":"16","key":"10.1002\/14651858.CD015125-BIB0013|cit13","doi-asserted-by":"publisher","first-page":"3545","DOI":"10.3390\/jcm10163545","article-title":"Ciclesonide inhaler treatment for mild-to-moderate COVID-19: a randomised, open-label, phase 2 trial","volume":"10","author":"Song","year":"2021","journal-title":"Journal of Clinical Medicine"},{"key":"10.1002\/14651858.CD015125-BIB0014|cit14","unstructured":"A clinical trial to study the effects of hydroxychloroquine, ciclesonide and ivermectin in treatment of moderate COVID-19 illness www.ctri.nic.in\/Clinicaltrials\/pdf_generate.php?trialid=43364&EncHid=&modid=&compid=%27,%2743364det%27"},{"key":"10.1002\/14651858.CD015125-BIB0015|cit15","unstructured":"Clinical trial to study the effect of budesonide taken through inhalation in mild COVID cases www.ctri.nic.in\/Clinicaltrials\/pdf_generate.php?trialid=47042&EncHid=&modid=&compid=%27,%2747042det%27"},{"key":"10.1002\/14651858.CD015125-BIB0016|cit16","unstructured":"CIMMCov: a randomised clinical study for prevention of severe disease in mild-to-moderate COVID-19 patients, using the inhaled medication ciclesonide www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2020-002208-37"},{"key":"10.1002\/14651858.CD015125-BIB0017|cit17","unstructured":"A multicenter, open-label, randomised controlled phase II study to evaluate the efficacy and safety of inhaled ciclesonide for asymptomatic and mild patients with COVID-19 (RACCO trial) jrct.niph.go.jp\/en-latest-detail\/jRCTs031190269"},{"issue":"12","key":"10.1002\/14651858.CD015125-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"e23830","DOI":"10.2196\/23830","article-title":"Efficacy and safety of inhaled ciclesonide in treating patients with asymptomatic or mild COVID-19 in the RACCO trial: protocol for a multicenter, open-label, randomised controlled trial","volume":"9","author":"Terada-Hirashima","year":"2020","journal-title":"JMIR Research Protocols"},{"key":"10.1002\/14651858.CD015125-BIB0019|cit19","unstructured":"Arrest respiratory failure from pneumonia (ARREST) clinicaltrials.gov\/ct2\/show\/record\/NCT04193878"},{"key":"10.1002\/14651858.CD015125-BIB0020|cit20","unstructured":"Trial of COVID-19 outpatient treatment in individuals with risk factors for aggravation (COVERAGEFrance) clinicaltrials.gov\/ct2\/show\/record\/NCT04356495"},{"key":"10.1002\/14651858.CD015125-BIB0021|cit21","unstructured":"Inhalation of ciclesonide for patients with COVID-19: a randomised open treatment study (HALT COVID-19) (HALT) clinicaltrials.gov\/ct2\/show\/NCT04381364"},{"key":"10.1002\/14651858.CD015125-BIB0022|cit22","unstructured":"Efficacy of inhaled therapies in the treatment of acute symptoms associated with COVID-19 (TRIVID) clinicaltrials.gov\/ct2\/show\/NCT04937543"},{"key":"10.1002\/14651858.CD015125-BIB0023|cit23","unstructured":"FLuticasone in cOvid Treatment (FLOT) clinicaltrials.gov\/ct2\/show\/NCT05054322"},{"key":"10.1002\/14651858.CD015125-BIB0024|cit24","unstructured":"Arformoterol\/budesonide for COVID-19 clinicaltrials.gov\/ct2\/show\/NCT05055414"},{"issue":"2","key":"10.1002\/14651858.CD015125-BIB0025|cit25","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1183\/09031936.06.00125404","article-title":"Corticosteroid effects on cell signalling","volume":"27","author":"Barnes","year":"2006","journal-title":"European Respiratory Journal"},{"issue":"9","key":"10.1002\/14651858.CD015125-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"e1003346","DOI":"10.1371\/journal.pmed.1003346","article-title":"Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: a living systematic review and meta-analysis","volume":"17","author":"Buitrago-Garcia","year":"2020","journal-title":"PLoS Medicine"},{"key":"10.1002\/14651858.CD015125-BIB0027|cit27","unstructured":"Core outcome set developers' response to COVID-19 www.comet-initiative.org\/Studies\/Details\/1538"},{"key":"10.1002\/14651858.CD015125-BIB0028|cit28","unstructured":"Pharmacologic treatments for COVID-19 patients \u2013 budesonide covid-nma.com\/living_data\/index.php?treatment1=budesonide&submit=Validate#comparisons_div"},{"issue":"3","key":"10.1002\/14651858.CD015125-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/bcp.12637","article-title":"Inhaled corticosteroids: potency, dose equivalence and therapeutic index","volume":"80","author":"Daley-Yates","year":"2015","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD015125-BIB0030|cit30","unstructured":"Deeks JJ Higgins JP Altman DG Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021 Available from training.cochrane.org\/handbook"},{"issue":"5","key":"10.1002\/14651858.CD015125-BIB0031|cit31","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1183\/09031936.00074905","article-title":"Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma","volume":"28","author":"Derendorf","year":"2006","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD015125-BIB0032|cit32","unstructured":"EndNote X9 Clarivate 2020"},{"issue":"2","key":"10.1002\/14651858.CD015125-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.jaci.2020.09.034","article-title":"Inhaled corticosteroids downregulate the SARS-CoV-2 receptor ACE2 in COPD through suppression of type I interferon","volume":"147","author":"Finney","year":"2021","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"6","key":"10.1002\/14651858.CD015125-BIB0034|cit34","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1136\/thx.47.6.404","article-title":"Inhaled corticosteroids: benefits and risks","volume":"47","author":"Geddes","year":"1992","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD015125-BIB0035|cit35","unstructured":"Use of ciclesonide for the treatment of respiratory diseases patents.google.com\/patent\/US8371292B2\/en"},{"key":"10.1002\/14651858.CD015125-BIB0036|cit36","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime) 2020"},{"issue":"5","key":"10.1002\/14651858.CD015125-BIB0037|cit37","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/S2213-2600(20)30167-","article-title":"Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection?","volume":"8","author":"Halpin","year":"2020","journal-title":"Lancet Respiratory Medicine"},{"key":"10.1002\/14651858.CD015125-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD015125-BIB0039|cit39","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020 Available from: training.cochrane.org\/handbook\/archive\/v6.1"},{"key":"10.1002\/14651858.CD015125-BIB0040|cit40","unstructured":"Higgins JP Lasserson T Chandler J Tovey D Thomas J Flemyng E Methodological expectations of Cochrane intervention reviews www.community.cochrane.org\/mecir-manual\/"},{"key":"10.1002\/14651858.CD015125-BIB0041|cit41","unstructured":"Higgins JP Savovic\u0301 J Page MJ Elbers RG Sterne JA Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021 Available from training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD015125-BIB0042|cit42","unstructured":"Higgins J Eldridge S Li T Chapter 23: Including variants on randomised trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated 2021). Cochrane, 2021 Available from training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD015125-BIB0043|cit43","unstructured":"Higgins JP Li T Deeks JJ Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021 Available from training.cochrane.org\/handbook"},{"issue":"10223","key":"10.1002\/14651858.CD015125-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD015125-BIB0045|cit45","unstructured":"Johns Hopkins University Mortality analyses coronavirus.jhu.edu\/data\/mortality"},{"key":"10.1002\/14651858.CD015125-BIB0046|cit46","unstructured":"Kluge S Janssens U Welte T Weber-Carstens S Sch\u00e4lte G S3 Guideline \u2013 recommendations for inpatient therapy of patients with COVID-19 www.awmf.org\/uploads\/tx_szleitlinien\/113-001LGl_S3_Empfehlungen-zur-stationaeren-Therapie-von-Patienten-mit-COVID-19_2022-03.pdf \u00a0 \u00a0"},{"issue":"9","key":"10.1002\/14651858.CD015125-BIB0047|cit47","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013825.pub2","article-title":"SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19","author":"Kreuzberger","year":"2021","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9","key":"10.1002\/14651858.CD015125-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"577","DOI":"10.7326\/M20-0504","article-title":"The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application","volume":"172","author":"Lauer","year":"2020","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD015125-BIB0049|cit49","unstructured":"Li T Higgins JP Deeks JJ Chapter 5: Collecting data. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020 Available from training.cochrane.org\/handbook\/archive\/v6.1"},{"issue":"3","key":"10.1002\/14651858.CD015125-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S1470-2045(20)30096-6","article-title":"Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China","volume":"21","author":"Liang","year":"2020","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD015125-BIB0051|cit51","unstructured":"Guidance for the production and publication of Cochrane living systematic reviews: Cochrane Reviews in living mode (Version December 2019) Available at community.cochrane.org\/review-production\/production-resources\/living-systematic-reviews"},{"issue":"8","key":"10.1002\/14651858.CD015125-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"e192","DOI":"10.1016\/S1473-3099(20)30483-7","article-title":"A minimal common outcome measure set for COVID-19 clinical research","volume":"20","author":"Marshall","year":"2020","journal-title":"Lancet Infectious Diseases"},{"issue":"13","key":"10.1002\/14651858.CD015125-BIB0053|cit53","doi-asserted-by":"publisher","first-page":"7001","DOI":"10.1073\/pnas.2002589117","article-title":"Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells","volume":"117","author":"Matsuyama","year":"2020","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1002\/14651858.CD015125-BIB0054|cit54","unstructured":"Microsoft Excel Microsoft Corporation 2018"},{"issue":"10","key":"10.1002\/14651858.CD015125-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"62","author":"Moher","year":"2009","journal-title":"Journal of Clinical Epidemiology"},{"issue":"7","key":"10.1002\/14651858.CD015125-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.chom.2021.06.006","article-title":"SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity","volume":"29","author":"Motozono","year":"2021","journal-title":"Cell Host Microbe"},{"issue":"24","key":"10.1002\/14651858.CD015125-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD015125-BIB0058|cit58","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1164\/rccm.202003-0821OC","article-title":"COVID-19-related genes in sputum cells in asthma. Relationship to demographic features and corticosteroids","volume":"202","author":"Peters","year":"2020","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"5","key":"10.1002\/14651858.CD015125-BIB0059|cit59","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013600.pub4","article-title":"Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review","author":"Piechotta","year":"2021","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD015125-BIB0060|cit60","doi-asserted-by":"publisher","first-page":"92","DOI":"10.4104\/pcrj.2012.00092","article-title":"Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD","volume":"22","author":"Price","year":"2012","journal-title":"Primary Care Respiratory Journal"},{"key":"10.1002\/14651858.CD015125-BIB0061|cit61","unstructured":"Review Manager Web (RevMan Web) The Cochrane Collaboration 2019"},{"key":"10.1002\/14651858.CD015125-BIB0062|cit62","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1056\/NEJMra050541","article-title":"Antiinflammatory action of glucocorticoids \u2013 new mechanisms for old drugs","volume":"353","author":"Rhen","year":"2005","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD015125-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jclinepi.2019.10.014","article-title":"GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions","volume":"119","author":"Santesso","year":"2020","journal-title":"Journal of Clinical Epidemiology"},{"issue":"6","key":"10.1002\/14651858.CD015125-BIB0064|cit64","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1016\/j.cell.2020.08.001","article-title":"Severe COVID-19 is marked by a dysregulated myeloid cell compartment","volume":"182","author":"Schulte-Schrepping","year":"2020","journal-title":"Cell"},{"key":"10.1002\/14651858.CD015125-BIB0065|cit65","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020 Available from training.cochrane.org\/handbook\/archive\/v6.1"},{"issue":"1","key":"10.1002\/14651858.CD015125-BIB0066|cit66","doi-asserted-by":"publisher","first-page":"m2980","DOI":"10.1136\/bmj.m2980","article-title":"Drug treatments for COVID-19: living systematic review and network meta-analysis (latest update)","volume":"370","author":"Siemieniuk","year":"2020","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD015125-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jclinepi.2019.10.015","article-title":"GRADE guidelines 27: how to calculate absolute effects for time-to-event outcomes in summary of findings tables and evidence profiles","volume":"118","author":"Skoetz","year":"2020","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD015125-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"13","key":"10.1002\/14651858.CD015125-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1001\/jama.2020.17023","article-title":"Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis","volume":"324","author":"Sterne","year":"2020","journal-title":"JAMA"},{"issue":"7","key":"10.1002\/14651858.CD015125-BIB0070|cit70","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013665","article-title":"Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19 disease","author":"Struyf","year":"2020","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD015125-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"issue":"696","key":"10.1002\/14651858.CD015125-BIB0072|cit72","first-page":"1","article-title":"Corticosteroid use in COVID-19 patients: a systematic review and meta-analysis on clinical outcomes","volume":"24","author":"Paassen","year":"2020","journal-title":"Critical Care"},{"issue":"3","key":"10.1002\/14651858.CD015125-BIB0073|cit73","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/S2213-2600(19)30417-5","article-title":"Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial","volume":"8","author":"Villar","year":"2020","journal-title":"Lancet Respiratory Medicine"},{"issue":"147","key":"10.1002\/14651858.CD015125-BIB0074|cit74","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1183\/16000617.0103-2017","article-title":"Exacerbations of COPD","volume":"27","author":"Viniol","year":"2018","journal-title":"European Respiratory Review"},{"issue":"8","key":"10.1002\/14651858.CD015125-BIB0075|cit75","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD014963","article-title":"Systemic corticosteroids for the treatment of COVID-19","author":"Wagner","year":"2021","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD015125-BIB0076|cit76","unstructured":"World Health Organization Cumulative number of reported probable cases of SARS www.who.int\/csr\/sars\/country\/2003_07_11\/en"},{"key":"10.1002\/14651858.CD015125-BIB0077|cit77","unstructured":"World Health Organization Middle East respiratory syndrome coronavirus (MERS-CoV) www.who.int\/emergencies\/mers-cov\/en"},{"key":"10.1002\/14651858.CD015125-BIB0078|cit78","unstructured":"World Health Organization Report of the WHO-China Joint Mission on coronavirus disease 2019 (COVID-19) www.who.int\/docs\/default-source\/coronaviruse\/who-china-joint-mission-on-covid-19-final-report"},{"key":"10.1002\/14651858.CD015125-BIB0079|cit79","unstructured":"World Health Organization Estimating mortality from COVID-19 \u2013 scientific brief www.who.int\/publications\/i\/item\/WHO-2019-nCoV-Sci-Brief-Mortality-2020.1"},{"key":"10.1002\/14651858.CD015125-BIB0080|cit80","unstructured":"WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection A minimal common outcome measure set for COVID-19 clinical research Lancet Infectious Diseases 2020 20 8 e192 7"},{"key":"10.1002\/14651858.CD015125-BIB0081|cit81","unstructured":"World Health Organization WHO Coronavirus Disease (COVID-19) Dashboard covid19.who.int"},{"key":"10.1002\/14651858.CD015125-BIB0082|cit82","unstructured":"World Health Organization Weekly epidemiological update \u2013 23 February 2021 www.who.int\/publications\/m\/item\/weekly-epidemiological-update---23-february-2021"},{"key":"10.1002\/14651858.CD015125-BIB0083|cit83","unstructured":"World Health Organization SARS-CoV-2 variants www.who.int\/csr\/don\/31-december-2020-sars-cov2-variants\/en"},{"key":"10.1002\/14651858.CD015125-BIB0084|cit84","unstructured":"Therapeutics and COVID-19: living guideline www.who.int\/publications\/i\/item\/WHO-2019-nCoV-therapeutics-2022.1 https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-therapeutics-2021.3"},{"key":"10.1002\/14651858.CD015125-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41586-020-2521-4","article-title":"Factors associated with COVID-19-related death using OpenSAFELY","volume":"584","author":"Williamson","year":"2020","journal-title":"Nature"},{"issue":"13","key":"10.1002\/14651858.CD015125-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1001\/jama.2020.2648","article-title":"Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention","volume":"323","author":"Wu","year":"2020","journal-title":"JAMA"},{"issue":"3","key":"10.1002\/14651858.CD015125-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.resinv.2019.12.005","article-title":"Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells","volume":"58","author":"Yamaya","year":"2020","journal-title":"Respiratory Investigation"},{"key":"10.1002\/14651858.CD015125-BIB0088|cit88","unstructured":"Wagner C Griesel M Fichtner F Skoetz N Mikolajewska A Stegemann M Efficacy and safety of inhaled corticosteroids for the treatment and prevention of SARS-CoV-2 infection (part of German Ecosystem Ceo-Sys) www.crd.york.ac.uk\/PROSPERO\/display_record.php?RecordID=266913"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T14:33:40Z","timestamp":1720276420000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD015125"}},"subtitle":[],"editor":[{"name":"Cochrane Airways Group","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,3,9]]},"references-count":88,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,3]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd015125","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,9]]}}}